ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,843,299 | -18.2% | 232,404 | -6.0% | 0.00% | 0.0% |
| Q2 2023 | $5,922,931 | +20.1% | 247,304 | -5.6% | 0.00% | +33.3% |
| Q1 2023 | $4,932,797 | +5.7% | 262,104 | -10.6% | 0.00% | 0.0% |
| Q4 2022 | $4,666,216 | -0.7% | 293,104 | +2.1% | 0.00% | 0.0% |
| Q3 2022 | $4,697,000 | +16.9% | 287,104 | +0.7% | 0.00% | 0.0% |
| Q2 2022 | $4,017,000 | -41.8% | 285,104 | 0.0% | 0.00% | -25.0% |
| Q1 2022 | $6,905,000 | +11.8% | 285,104 | +7.7% | 0.00% | 0.0% |
| Q4 2021 | $6,176,000 | +40.5% | 264,604 | 0.0% | 0.00% | +33.3% |
| Q3 2021 | $4,395,000 | -31.9% | 264,604 | 0.0% | 0.00% | -25.0% |
| Q2 2021 | $6,454,000 | -8.2% | 264,604 | -2.9% | 0.00% | -20.0% |
| Q1 2021 | $7,028,000 | -51.2% | 272,404 | +1.1% | 0.01% | -50.0% |
| Q4 2020 | $14,402,000 | +31.8% | 269,404 | +1.7% | 0.01% | +11.1% |
| Q3 2020 | $10,927,000 | -13.3% | 264,904 | +1.8% | 0.01% | -18.2% |
| Q2 2020 | $12,607,000 | +33.2% | 260,104 | +16.1% | 0.01% | +10.0% |
| Q1 2020 | $9,464,000 | +6.6% | 224,004 | +8.0% | 0.01% | +11.1% |
| Q4 2019 | $8,877,000 | +21.3% | 207,504 | +2.0% | 0.01% | +12.5% |
| Q3 2019 | $7,321,000 | +36.5% | 203,404 | +1.3% | 0.01% | +33.3% |
| Q2 2019 | $5,365,000 | -2.9% | 200,704 | -2.5% | 0.01% | 0.0% |
| Q1 2019 | $5,526,000 | +68.0% | 205,804 | +1.2% | 0.01% | +50.0% |
| Q4 2018 | $3,289,000 | -8.6% | 203,404 | +17.3% | 0.00% | 0.0% |
| Q3 2018 | $3,600,000 | +36.0% | 173,404 | 0.0% | 0.00% | +33.3% |
| Q2 2018 | $2,648,000 | -32.0% | 173,404 | 0.0% | 0.00% | -40.0% |
| Q1 2018 | $3,896,000 | -22.4% | 173,404 | +4.0% | 0.01% | 0.0% |
| Q4 2017 | $5,022,000 | -18.2% | 166,804 | +2.4% | 0.01% | -28.6% |
| Q3 2017 | $6,137,000 | +35.1% | 162,904 | 0.0% | 0.01% | +40.0% |
| Q2 2017 | $4,543,000 | -17.3% | 162,904 | +2.0% | 0.01% | -28.6% |
| Q1 2017 | $5,491,000 | +20.7% | 159,704 | +1.2% | 0.01% | 0.0% |
| Q4 2016 | $4,551,000 | -6.7% | 157,804 | +2.9% | 0.01% | -12.5% |
| Q3 2016 | $4,880,000 | -0.4% | 153,404 | +1.6% | 0.01% | 0.0% |
| Q2 2016 | $4,902,000 | +16.2% | 151,004 | -3.4% | 0.01% | 0.0% |
| Q1 2016 | $4,219,000 | +12.4% | 156,304 | +48.4% | 0.01% | -11.1% |
| Q4 2015 | $3,754,000 | +7.8% | 105,300 | 0.0% | 0.01% | 0.0% |
| Q3 2015 | $3,482,000 | -9.4% | 105,300 | +14.7% | 0.01% | -10.0% |
| Q2 2015 | $3,845,000 | +31.4% | 91,800 | +2.2% | 0.01% | +25.0% |
| Q1 2015 | $2,927,000 | +3.9% | 89,800 | +1.2% | 0.01% | -27.3% |
| Q4 2014 | $2,816,000 | +31.7% | 88,700 | +2.7% | 0.01% | +37.5% |
| Q3 2014 | $2,139,000 | +8.4% | 86,400 | -1.1% | 0.01% | +14.3% |
| Q2 2014 | $1,974,000 | -7.1% | 87,400 | 0.0% | 0.01% | -12.5% |
| Q1 2014 | $2,126,000 | +53.3% | 87,400 | +57.5% | 0.01% | +60.0% |
| Q4 2013 | $1,387,000 | -9.0% | 55,500 | 0.0% | 0.01% | -16.7% |
| Q3 2013 | $1,525,000 | +44.8% | 55,500 | -4.3% | 0.01% | +20.0% |
| Q2 2013 | $1,053,000 | – | 58,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |